Eli Lilly in Alzey: billion dollar investment or secret price agreements?

Eli Lilly in Alzey: billion dollar investment or secret price agreements?

The US Pharmariese Eli Lilly is suspected of making his billion-dollar investment in a new work in Alzey on a change in the law that could give him advantages in pricing. Despite the company's claims not to have done this, internal documents, which have been disclosed by several media, including WDR and NDR, have this impression. Eli Lilly Planned, up to a billion-dollar investment in Rhineland-Palatinate, to request the secrecy of discounts on new medication as a condition.

The current draft of the Medical Research Act, which has already been decided by the Bundestag and the Federal Council, could enable Eli Lilly to keep discounts on his new diabetes medication Mounjaro secret, while the health insurance companies are no longer transparently informed about these prices. Experts fear that this could lead to an increase in medication prices, since the public can no longer understand which price agreements are actually made. Eli Lilly negated that he has put pressure on the federal government and claims that the decision about the investments had been made regardless of the talks about secret prices. More on this can be found in a report on www.rheinpfalz.de .